What is ORGO's health score?

Organogenesis Holdings Inc. (ORGO) has a TradeApes health score of 44 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ORGO's estimated fair value?

Based on our 5-year discounted cash flow model, Organogenesis Holdings Inc.'s estimated fair value is $0.94 per share, representing a -62.0% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ORGO undervalued or overvalued?

Our model currently rates ORGO as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ORGO... Refresh in a moment for the full analysis.

Organogenesis Holdings Inc. (ORGO)

Healthcare Overvalued low weak

$2.48

Updated: 2026-06-05

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

30 Weak

Relative Value

28 Stressed

Capital Allocation

70 Healthy

Risk

80 Strong

Est. Fair Value $0.94

DCF Upside -62.0%

Sector Rank #3310 of 6798

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Extreme P/E — above 45×, very high expectations embedded in price

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.